HCV and the Female Patient: Reproductive Health Considerations
Dates this webinar will be offered:
- Discuss sexual and reproductive health issues for women with Hepatitis C
- Discuss best practices in HCV management for pregnant and lactating patients
- Counsel patients with HCV regarding the risks and benefits of HCV treatment during pregnancy and lactation
- Communicate with patients about the importance of HCV screening as well as the implications of positive antibody results, and effectively describe the treatment options and long-term outcomes
Continuing Medical Education Credits: continuing Medical Education Credits: Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. ARHP designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education Credits: Continuing Nursing Education Credits: edit commensurate with the extent of their participation in the activity. Continuing medical education (CME) for physicians. ARHP designates 1.0 contact hours.
Continuing Pharmacy Education Credits: ARHP is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hours (1.0 CEUs) of continuing pharmacy education credit as recognized by the Accreditation Council for Pharmacy Education.
This activity is sponsored by the Association of Reproductive Health Professionals.
This project and webinar is funded through an independent educational grant from Gilead.
All individuals in a position to influence the content of this activity must disclose relevant financial relationship(s) with commercial interests and the nature of the relationship. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by or used on patients.
- Austin Nation, PhD, RN, PHN, has nothing to disclose.
- David English, MD, has nothing to disclose.
- Jenna Kawamoto, PharmD, has nothing to disclose.
- Doris Quintanilla (program manager) has nothing to disclose.